Figure 7. Evaluating the immunotherapeutic response of LUAD subtypes. The expression of immune checkpoint molecules including (A) TIGIT, (B) ICOS, (C) TIM-3 (HAVCR2), (D) CTLA4, and (E) PD-L1 (CD274) between patients with high and low risk. (F) Stemness index values of patients in high- and low-risk groups. (G) Immunotherapeutic responses of patients with high and low risk. LUAD, lung adenocarcinoma; PD-L1, programmed cell death-ligand 1.